be assure that BX made a lot of money..nice to have confidence in their ability.. otherwise why invest???
February 28, 2014
09:15 EDT QCOR Questcor continues lower as FDA says reviewing Acthar lab test results
Shares of Questcor (QCOR) are down 3.8% in pre-market trading to $64.90 after falling 9% yesterday following Citron Research claiming the company's Acthar drug faces "severe risk" of being pulled from the market by the FDA. Following the Citron report, the FDA stated in an e-mail to Bloomberg that it had received a letter and lab results from an attorney as mentioned by Citron and was reviewing the materials. Questcor's COO Steve Cartt stated in an e-mail to Bloomberg First Word that "each Acthar lot meets FDA-mandated specifications which have not changed over several decades," the news service reported.
Filed pursuant to Rule 424(b)(5)
Registration No. 333-178190
(to Prospectus dated December 22, 2011)
INTELLIPHARMACEUTICS INTERNATIONAL INC.
This Prospectus Supplement supplements certain information in our Prospectus dated December 22, 2011 (the “Prospectus”), as supplemented by our prior Prospectus Supplement dated November 27, 2013 (the “2013 Supplement”) and our prior Prospectus Supplement dated January 17, 2014 (the “2014 Supplement”). This Prospectus Supplement should be read in conjunction with the Prospectus, the 2013 Supplement and the 2014 Supplement, and is qualified by reference thereto, except to the extent that the information herein supersedes the information contained in the Prospectus, the 2013 Supplement and the 2014 Supplement. This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus, the 2013 Supplement and the 2014 Supplement, including any amendments or supplements thereto.
Through February 26, 2014, we have sold our common shares through Roth Capital Partners, LLC (“Roth”) under the equity distribution agreement we entered into with Roth for an aggregate purchase price of $4,994,014.00. We are filing this Prospectus Supplement because we are now subject to General Instruction I.B.5 of Form F-3, which limits the amounts that we may sell under the Registration Statement of which this Prospectus Supplement and the Prospectus, the 2013 Supplement and the 2014 Supplement are a part. As a result of these limitations and the current public float (or the aggregate market value of the registrant’s outstanding common stock held by non-affiliates) of our common shares, and in accordance with the terms of our equity distribution agreement with Roth, we may currently offer and sell additional common shares having an aggregate offering price of up to $11,855,986 through at-the-market issuances on the NASDAQ or otherwise. However, in the event our public float subsequently equals or exceeds $75,000,000, we may sell additional amounts under the equity distribution agreement and the Registration Statement of which this Prospectus Supplement and the Prospectus, the 2013 Supplement and the 2014 Supplement are a part, as the limitations on sales under General Instruction I.B.5 of Form F-3 would not then apply.
Our common shares are listed for trading on the Toronto Stock Exchange under the symbol “I” and on The NASDAQ Capital Market under the symbol “IPCI”. On February 26, 2014, the closing sale price of the common shares as reported by the Toronto Stock Exchange and The NASDAQ Capital Market was Cdn$4.33 and $3.90, respectively. On February 26, 2014, the aggregate market value of our outstanding common shares held by non-affiliates was $69,110,216, based on our 22,819,711 outstanding common shares, of which 16,653,064 were held by non-affiliates, and a per share price of $4.15, the closing sale price of our common shares on February 13, 2014 (which is the highest closing price in the last 60 days). We have sold or offered securities having an aggregate market value of approximately $9,636,113 pursuant to General Instruction I.B.5 of Form F-3 during the prior twelve calendar month period that ends on and includes the date of this Prospectus Supplement.
Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Risk Factors” beginning on page S-4 of the 2013 Supplement, and under similar headings in the other documents that are incorporated by reference therein (and any amendments thereto), including our most recent annual report on Form 20-F.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
Prospectus Supplement dated February 27, 2014
stocastics showing buy signal and trading above 50 dma of 3.75.. a nice long consoladation menas a nice move on the breaking of the pattern.. which I think will be up.. http://finance.yahoo.com/q/ta?t=1y&l=on&z=l&q=b&p=m50%2Cm100%2Cm200%2Cv&a=m26-12-9%2Cr14%2Css&c=&s=ipci&ql=1
Sentiment: Strong Buy
when it shows 4 it means 400 shares...
seems no ones follows the jerk psucker???COVERAGE REITERATED: Blackstone (BX) reiterated by Argus. Reiterated rating Buy. 02/27 11:27 AM
Get more news on:SYMBOLS: BXNEWS TYPE: Ratings: Upgrades and DowngradesSECTORS: Financials, Capital Markets
Sentiment: Strong Buy
they did buy lot of stock at avrage 55 a share...should be attractive withthis sell off
the person who posted a positve OBV yesterday is wrong.. thre was a 460,000 shares downtick yesterday morning which set the tone for trading and a Negative OBV for the day.. your source is wrong..dont follow it..
February 27, 2014
06:17 EDT GS, KKR, JPM, BX, BAC Biomet, preparing for IPO, selects banks, Reuters reports
U.S. medical device maker Biomet hired underwriters for an IPO for later this year, sources say, reports Reuters. Sources added that the offering could come in the first half of this year and raise over $1B. Biomet's owners -- Blackstone Group (BX), Goldman Sachs's (GS) private equity arm, KKR (KKR) and TPG Capital -- picked Bank of America Merrill Lynch (BAC), Goldman Sachs Group (GS) and JPMorgan Chase (JPM) to lead the IPO, sources say. Reference Link
A/D line was DOWN 600,000 shares as shown on Fidelity Active Pro....no way it could be up with those hugh down blocks.....
1/21 high 33.41, 2/3 high 33.33 and today 33.29
13,200 to buy at 3.85 and 1,500 to sell at 3.86...on balance volume plus 30,000 ,,chart looks good with stocastics looking to give a buy....
February 25, 2014
16:13 EDT QCOR Questcor says management, board working closely to explore strategies
The company said, "As we turn to 2014, our highest priority is to continue our commercial momentum, while further building the body of scientific evidence for Acthar and actively exploring various strategic alternatives. Management is working closely with the Board's newly formed Strategic Advisory Committee to support the Company's investigation and evaluation of potential strategies to use its future potential cash flow to generate long-term growth and value for shareholders, patients and the healthcare community."
QCOR, Q4, Operating Metrics Released 02/25 01:16 PM
04:16 PM EST, 02/25/2014 (MT Newswires) -- Company Name: QUESTCOR PHARMA Quarter: FQ -2013 - Q4, 2013-12
REVENUE : BioVectra
--- Actual: 12.6, Est: 8.9, Surprise (vs. consensus): 41.10%
Get more news on:SYMBOLS: QCORNEWS TYPE: Company News, Extended Trading, Post-Market MoversSECTORS: Health Care, Pharmaceuticals